{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,21]],"date-time":"2024-02-21T00:13:45Z","timestamp":1708474425209},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2023,11,16]],"date-time":"2023-11-16T00:00:00Z","timestamp":1700092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,11,16]],"date-time":"2023-11-16T00:00:00Z","timestamp":1700092800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Chirurgie"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1007\/s00104-023-01993-9","type":"journal-article","created":{"date-parts":[[2023,11,16]],"date-time":"2023-11-16T20:03:51Z","timestamp":1700165031000},"page":"192-199","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Personalisiertes Vorgehen beim anaplastischen Schilddr\u00fcsenkarzinom","Personalized approach to anaplastic thyroid carcinoma"],"prefix":"10.1007","volume":"95","author":[{"given":"Sabine","family":"W\u00e4chter","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Detlef K.","family":"Bartsch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabeth","family":"Maurer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,11,16]]},"reference":[{"issue":"3","key":"1993_CR1","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1089\/thy.2020.0944","volume":"31","author":"KC Bible","year":"2021","unstructured":"Bible\u00a0KC et\u00a0al (2021) 2021 American Thyroid Association guidelines for management of patients with anaplastic thyroid cancer. Thyroid 31(3):337\u2013386. https:\/\/doi.org\/10.1089\/thy.2020.0944","journal-title":"Thyroid"},{"issue":"6","key":"1993_CR2","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1016\/j.clon.2010.03.013","volume":"22","author":"RC Smallridge","year":"2010","unstructured":"Smallridge\u00a0RC, Copland\u00a0JA (2010) Anaplastic thyroid carcinoma: pathogenesis and emerging therapies. Clin Oncol 22(6):486\u2013497. https:\/\/doi.org\/10.1016\/j.clon.2010.03.013","journal-title":"Clin Oncol"},{"issue":"8","key":"1993_CR3","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1007\/s00761-021-00988-7","volume":"27","author":"V Arndt","year":"2021","unstructured":"Arndt\u00a0V, Dahm\u00a0S, Kraywinkel\u00a0K (2021) Krebspr\u00e4valenz in Deutschland 2017. Onkologe 27(8):717\u2013723. https:\/\/doi.org\/10.1007\/s00761-021-00988-7","journal-title":"Onkologe"},{"key":"1993_CR4","unstructured":"Haddad RI et\u00a0al (2015) Anaplastic thyroid carcinoma, version\u00a02.2015: clinical practice guidelines in oncology HHS public access, J\u00a0Natl Compr Canc Netw. https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC4986600\/pdf\/nihms806782.pdf. Zugegriffen: 31. M\u00e4rz 2020"},{"key":"1993_CR5","doi-asserted-by":"publisher","DOI":"10.1007\/s00405-020-05853-8","author":"S W\u00e4chter","year":"2020","unstructured":"W\u00e4chter\u00a0S et\u00a0al (2020) Anaplastic thyroid carcinoma: changing trends of treatment strategies and associated overall survival. Eur Arch Otorhinolaryngol. https:\/\/doi.org\/10.1007\/s00405-020-05853-8","journal-title":"Eur Arch Otorhinolaryngol"},{"issue":"7","key":"1993_CR6","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1002\/cncr.20936","volume":"103","author":"E Kebebew","year":"2005","unstructured":"Kebebew\u00a0E et\u00a0al (2005) Anaplastic thyroid carcinoma. Treatment outcome and prognostic factors. Cancer 103(7):1330\u20131335. https:\/\/doi.org\/10.1002\/cncr.20936","journal-title":"Cancer"},{"issue":"9","key":"1993_CR7","first-page":"5888","volume":"11","author":"B Lin","year":"2019","unstructured":"Lin\u00a0B et\u00a0al (2019) \u2018The incidence and survival analysis for anaplastic thyroid cancer: a\u00a0SEER database analysis. Am J Transl Res 11(9):5888\u20135896 (Available at: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/31632557 (Accessed: 2\u00a0January 2020))","journal-title":"Am J Transl Res"},{"issue":"9","key":"1993_CR8","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1001\/jamaoncol.2020.3362","volume":"6","author":"A Maniakas","year":"2020","unstructured":"Maniakas\u00a0A et\u00a0al (2020) Evaluation of overall survival in patients with anaplastic thyroid carcinoma, 2000\u20132019. JAMA Oncol 6(9):1397. https:\/\/doi.org\/10.1001\/jamaoncol.2020.3362","journal-title":"JAMA Oncol"},{"issue":"26","key":"1993_CR9","doi-asserted-by":"publisher","first-page":"42613","DOI":"10.18632\/oncotarget.17300","volume":"8","author":"V Tiedje","year":"2017","unstructured":"Tiedje\u00a0V et\u00a0al (2017) NGS based identification of mutational hotspots for targeted therapy in anaplastic thyroid carcinoma. Oncotarget 8(26):42613\u201342620. https:\/\/doi.org\/10.18632\/oncotarget.17300","journal-title":"Oncotarget"},{"key":"1993_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.12.014","author":"V Subbiah","year":"2022","unstructured":"Subbiah\u00a0V et al (2022) Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase\u00a0II ROAR basket study. Ann Oncol. https:\/\/doi.org\/10.1016\/j.annonc.2021.12.014","journal-title":"Ann Oncol"},{"issue":"Suppl 1","key":"1993_CR11","doi-asserted-by":"publisher","first-page":"S28","DOI":"10.21037\/gs.2019.10.18","volume":"9","author":"SM Ferrari","year":"2020","unstructured":"Ferrari\u00a0SM et\u00a0al (2020) Novel treatments for anaplastic thyroid carcinoma. Gland Surg 9(Suppl 1):S28\u2013S42. https:\/\/doi.org\/10.21037\/gs.2019.10.18","journal-title":"Gland Surg"},{"key":"1993_CR12","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1530\/EJE-21-1259","volume":"186","author":"SG Waguespack","year":"2022","unstructured":"Waguespack\u00a0SG et al (2022) Efficacy and safety of larotrectinib in patients with TRK fusion-positive thyroid carcinoma. Eur J Endocrinol 186:631\u2013643. https:\/\/doi.org\/10.1530\/EJE-21-1259","journal-title":"Eur J Endocrinol"},{"key":"1993_CR13","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1056\/NEJMoa1714448","volume":"378","author":"A Drilon","year":"2018","unstructured":"Drilon\u00a0A, Laetsch\u00a0TW, Kummar\u00a0S et al (2018) Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children. N\u00a0Engl J Med 378:731\u2013739","journal-title":"N Engl J Med"},{"key":"1993_CR14","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/S1470-2045(19)30691-6","volume":"21","author":"RC Doebele","year":"2020","unstructured":"Doebele\u00a0RC, Drilon\u00a0A, Paz-Ares\u00a0L et al (2020) Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase\u00a01\u20132\u00a0trials. Lancet Oncol 21:271\u2013282","journal-title":"Lancet Oncol"},{"key":"1993_CR15","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1056\/NEJMoa2005651","volume":"383","author":"LJ Wirth","year":"2020","unstructured":"Wirth\u00a0LJ, Sherman\u00a0E, Robinson\u00a0B et al (2020) Efficacy of selpercatinib in RET-altered thyroid cancers. N\u00a0Engl J Med 383:825\u2013835","journal-title":"N Engl J Med"},{"key":"1993_CR16","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/S2213-8587(21)00120","volume":"9","author":"V Subbiah","year":"2021","unstructured":"Subbiah\u00a0V, Hu\u00a0MI, Wirth\u00a0LJ, Schuler\u00a0M, Mansfield\u00a0AS, Curigliano\u00a0G, Brose\u00a0MS, Zhu\u00a0VW, Leboulleux\u00a0S, Bowles\u00a0DW et al (2021) Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a\u00a0multi-cohort, open-label, registrational, phase\u00a01\/2\u00a0study. Lancet Diabetes Endocrinol 9:491\u2013501. https:\/\/doi.org\/10.1016\/S2213-8587(21)00120","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1993_CR17","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1158\/1078-0432.CCR-17-2297","volume":"24","author":"GJ Hanna","year":"2018","unstructured":"Hanna\u00a0GJ, Busaidy\u00a0NL, Chau\u00a0NG, Wirth\u00a0LJ, Barletta\u00a0JA, Calles\u00a0A, Haddad\u00a0RI, Kraft\u00a0S, Cabanillas\u00a0ME, Rabinowits\u00a0G et al (2018) Genomic correlates of response to everolimus in aggressive radioiodine-refractory thyroid cancer: a\u00a0phase\u00a0II study. Clin Cancer Res 24:1546\u20131553. https:\/\/doi.org\/10.1158\/1078-0432.CCR-17-2297","journal-title":"Clin Cancer Res"},{"key":"1993_CR18","doi-asserted-by":"publisher","first-page":"106","DOI":"10.3389\/fonc.2019.00106","volume":"9","author":"EJ Harris","year":"2019","unstructured":"Harris\u00a0EJ, Hanna\u00a0GJ, Chau\u00a0N, Rabinowits\u00a0G, Haddad\u00a0R, Margalit\u00a0DN, Schoenfeld\u00a0J, Tishler\u00a0RB, Barletta\u00a0JA, Nehs\u00a0M et\u00a0al (2019) Everolimus in anaplastic thyroid cancer: a\u00a0case series. Front Oncol 9:106. https:\/\/doi.org\/10.3389\/fonc.2019.00106","journal-title":"Front Oncol"},{"issue":"5","key":"1993_CR19","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1089\/thy.2012.0103","volume":"23","author":"P Savvides","year":"2013","unstructured":"Savvides\u00a0P et\u00a0al (2013) Phase\u00a0II trial of Sorafenib in patients with advanced anaplastic carcinoma of the thyroid. Thyroid 23(5):600\u2013604. https:\/\/doi.org\/10.1089\/thy.2012.0103","journal-title":"Thyroid"},{"issue":"9","key":"1993_CR20","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1089\/thy.2016.0621","volume":"27","author":"Y Ito","year":"2017","unstructured":"Ito\u00a0Y et\u00a0al (2017) Sorafenib in Japanese patients with locally advanced or metastatic medullary thyroid carcinoma and Anaplastic thyroid carcinoma. Thyroid 27(9):1142\u20131148. https:\/\/doi.org\/10.1089\/thy.2016.0621","journal-title":"Thyroid"},{"issue":"21","key":"1993_CR21","doi-asserted-by":"publisher","first-page":"4114","DOI":"10.1002\/cncr.30861","volume":"123","author":"EJ Sherman","year":"2017","unstructured":"Sherman\u00a0EJ et al (2017) Phase\u00a02\u00a0study evaluating the combination of sorafenib and temsirolimus in the treatment of radioactive iodine-refractory thyroid cancer. Cancer 123(21):4114\u20134121. https:\/\/doi.org\/10.1002\/cncr.30861","journal-title":"Cancer"},{"issue":"7","key":"1993_CR22","doi-asserted-by":"publisher","first-page":"717","DOI":"10.2217\/fon-2018-0557","volume":"15","author":"S Takahashi","year":"2019","unstructured":"Takahashi\u00a0S et\u00a0al (2019) A Phase\u00a0II study of the safety and efficacy of lenvatinib in patients with advanced thyroid cancer. Future Oncol 15(7):717\u2013726. https:\/\/doi.org\/10.2217\/fon-2018-0557","journal-title":"Future Oncol"},{"issue":"2","key":"1993_CR23","doi-asserted-by":"publisher","first-page":"138","DOI":"10.3892\/mco.2019.1964","volume":"12","author":"H Iwasaki","year":"2020","unstructured":"Iwasaki\u00a0H et\u00a0al (2020) Lenvatinib vs. palliative therapy for stage IVC anaplastic thyroid cancer. mol clin onc 12(2):138\u2013143. https:\/\/doi.org\/10.3892\/mco.2019.1964","journal-title":"mol clin onc"},{"key":"1993_CR24","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1089\/thy.2017.0285","volume":"28","author":"PC Iyer","year":"2018","unstructured":"Iyer\u00a0PC, Dadu\u00a0R, Ferrarotto\u00a0R et al (2018) Real-world experience with targeted therapy for the treatment of anaplastic thyroid carcinoma. Thyroid 28:79\u201387","journal-title":"Thyroid"},{"key":"1993_CR25","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1089\/thy.2016.0627","volume":"27","author":"NM Iniguez-Ariza","year":"2017","unstructured":"Iniguez-Ariza\u00a0NM, Ryder\u00a0MM, Hilger\u00a0CR, Bible\u00a0KC (2017) Salvage lenvatinib therapy in metastatic anaplastic thyroid cancer. Thyroid 27:923\u2013927","journal-title":"Thyroid"},{"issue":"7","key":"1993_CR26","doi-asserted-by":"publisher","first-page":"3871","DOI":"10.21873\/anticanres.13537","volume":"39","author":"Y Staub","year":"2019","unstructured":"Staub\u00a0Y et al (2019) Clinical characteristics associated with Lenvatinib-induced fistula and tumor-related bleeding in patients with thyroid cancer. Anticancer Res 39(7):3871\u20133878. https:\/\/doi.org\/10.21873\/anticanres.13537","journal-title":"Anticancer Res"},{"key":"1993_CR27","doi-asserted-by":"publisher","DOI":"10.23937\/2378-3419\/3\/6\/1074","author":"K Suyama","year":"2016","unstructured":"Suyama\u00a0K (2016) Massive arterial bleeding after Lenvatinib therapy for thyroid cancer. Int J Cancer Clin Res. https:\/\/doi.org\/10.23937\/2378-3419\/3\/6\/1074","journal-title":"Int J Cancer Clin Res"},{"issue":"3","key":"1993_CR28","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1002\/cncy.22224","volume":"128","author":"M Dell\u2019Aquila","year":"2020","unstructured":"Dell\u2019Aquila\u00a0M et al (2020) PD-L1 and thyroid cytology: a\u00a0possible diagnostic and prognostic marker. Cancer 128(3):177\u2013189. https:\/\/doi.org\/10.1002\/cncy.22224","journal-title":"Cancer"},{"issue":"6","key":"1993_CR29","doi-asserted-by":"publisher","first-page":"1943","DOI":"10.1210\/jc.2016-3756","volume":"102","author":"AV Chintakuntlawar","year":"2017","unstructured":"Chintakuntlawar\u00a0AV et al (2017) Expression of PD\u20111 and PD-L1 in Anaplastic thyroid cancer patients treated with multimodal therapy: results from a\u00a0retrospective study. J\u00a0Clin Endocrinol Metab 102(6):1943\u20131950. https:\/\/doi.org\/10.1210\/jc.2016-3756","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"1993_CR30","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1007\/s12020-019-01865-5","volume":"64","author":"S Cantara","year":"2019","unstructured":"Cantara\u00a0S et al (2019) Blockade of the programmed death ligand 1 (PD-L1) as potential therapy for anaplastic thyroid cancer. Endocrine 64(1):122\u2013129. https:\/\/doi.org\/10.1007\/s12020-019-01865-5","journal-title":"Endocrine"},{"issue":"1","key":"1993_CR31","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s40425-018-0378-y","volume":"6","author":"PC Iyer","year":"2018","unstructured":"Iyer\u00a0PC et\u00a0al (2018) Salvage pembrolizumab added to kinase inhibitor therapy for the treatment of anaplastic thyroid carcinoma. J\u00a0Immunother Cancer 6(1):68. https:\/\/doi.org\/10.1186\/s40425-018-0378-y","journal-title":"J Immunother Cancer"},{"key":"1993_CR32","doi-asserted-by":"publisher","DOI":"10.1089\/THY.2020.0322","author":"C Dierks","year":"2021","unstructured":"Dierks\u00a0C, Seufert\u00a0J, Aumann\u00a0K et\u00a0al (2021) The Lenvatinib\/Pembrolizumab combination is an effective treatment option for anaplastic and poorly differentiated thyroid carcinoma. Thyroid. https:\/\/doi.org\/10.1089\/THY.2020.0322","journal-title":"Thyroid"},{"key":"1993_CR33","doi-asserted-by":"publisher","first-page":"6514","DOI":"10.1200\/JCO.2020.38.15_suppl.6514","volume":"38","author":"ME Cabanillas","year":"2020","unstructured":"Cabanillas\u00a0ME, Dadu\u00a0R, Ferrarotto\u00a0R, Liu\u00a0S, Fellman\u00a0BM, Gross\u00a0ND, Gule-Monroe\u00a0M, Lu\u00a0C, Grosu\u00a0H, Williams\u00a0MD et al (2020) Atezolizumab combinations with targeted therapy for Anaplastic Thyroid Carcinoma (ATC). J\u00a0Clin Oncol 38:6514","journal-title":"J Clin Oncol"},{"key":"1993_CR34","doi-asserted-by":"publisher","first-page":"2620","DOI":"10.1200\/JCO.19.02727","volume":"38","author":"J Capdevila","year":"2020","unstructured":"Capdevila\u00a0J, Wirth\u00a0LJ, Ernst\u00a0T et al (2020) PD\u20111 Blockade in anaplastic thyroid carcinoma. J\u00a0Clin Oncol 38:2620\u20132627","journal-title":"J Clin Oncol"},{"issue":"7","key":"1993_CR35","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1089\/thy.2018.0060","volume":"28","author":"ME Cabanillas","year":"2018","unstructured":"Cabanillas\u00a0ME et al (2018) Neoadjuvant BRAF- and immune-directed therapy for anaplastic thyroid carcinoma. Thyroid 28(7):945\u2013951. https:\/\/doi.org\/10.1089\/thy.2018.0060","journal-title":"Thyroid"},{"issue":"3","key":"1993_CR36","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1007\/S00405-023-07827-Y","volume":"280","author":"E Maurer","year":"2023","unstructured":"Maurer\u00a0E et al (2023) Mutation-based, short-term \u201cneoadjuvant\u201d treatment allows resectability in stage IVB and C anaplastic thyroid cancer. Eur Arch Otorhinolaryngol 280(3):1509\u20131518. https:\/\/doi.org\/10.1007\/S00405-023-07827-Y","journal-title":"Eur Arch Otorhinolaryngol"},{"issue":"5","key":"1993_CR37","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1111\/cen.14679","volume":"96","author":"HC McCrary","year":"2022","unstructured":"McCrary\u00a0HC et\u00a0al (2022) Mutation based approaches to the treatment of anaplastic thyroid cancer. Clin Endocrinol 96(5):734\u2013742. https:\/\/doi.org\/10.1111\/cen.14679","journal-title":"Clin Endocrinol"},{"issue":"8","key":"1993_CR38","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1089\/thy.2019.0133","volume":"29","author":"JR Wang","year":"2019","unstructured":"Wang\u00a0JR et al (2019) Complete surgical resection following neoadjuvant dabrafenib plus trametinib in BRAF V600E-mutated anaplastic thyroid carcinoma. Thyroid 29(8):1036\u20131043. https:\/\/doi.org\/10.1089\/thy.2019.0133","journal-title":"Thyroid"},{"key":"1993_CR39","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.ijscr.2016.06.013","volume":"25","author":"S Eckhardt","year":"2016","unstructured":"Eckhardt\u00a0S et al (2016) Individualized multimodal treatment strategy for anaplastic thyroid carcinoma-case report of long-term remission and review of literature. Int J Surg Case Rep 25:174\u2013178. https:\/\/doi.org\/10.1016\/j.ijscr.2016.06.013","journal-title":"Int J Surg Case Rep"},{"issue":"5","key":"1993_CR40","doi-asserted-by":"publisher","first-page":"115","DOI":"10.3390\/jcm7050115","volume":"7","author":"S W\u00e4chter","year":"2018","unstructured":"W\u00e4chter\u00a0S et\u00a0al (2018) Individualised multimodal treatment strategies for anaplastic and poorly differentiated thyroid cancer. J\u00a0Clin Med 7(5):115. https:\/\/doi.org\/10.3390\/jcm7050115","journal-title":"J Clin Med"}],"container-title":["Die Chirurgie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00104-023-01993-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00104-023-01993-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00104-023-01993-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,20]],"date-time":"2024-02-20T10:03:06Z","timestamp":1708423386000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00104-023-01993-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,16]]},"references-count":40,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["1993"],"URL":"https:\/\/doi.org\/10.1007\/s00104-023-01993-9","relation":{},"ISSN":["2731-6971","2731-698X"],"issn-type":[{"value":"2731-6971","type":"print"},{"value":"2731-698X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,16]]},"assertion":[{"value":"24 October 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 November 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"S.\u00a0W\u00e4chter, D.K.\u00a0Bartsch und E.\u00a0Maurer geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien. Alle Patienten, die \u00fcber Bildmaterial oder anderweitige Angaben innerhalb des Manuskripts zu identifizieren sind, haben hierzu ihre schriftliche Einwilligung gegeben.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}